EFFICACY OF SERUM BILE ACIDS IN DETERMINING HEPATOBILIARY DISEASE IN CF

血清胆汁酸在确定 CF 患者肝胆疾病中的功效

• 批准号: 6276225
• 负责人: MICHAEL R. NARKEWICZ
• 金额: $ 1.86万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276225
• 关键词: biomarker; cholanate compound; clinical research; cystic fibrosis; dietary trace element; fasting; galactose; human subject; liver disorder diagnosis; manganese; nutrition related tag; serum

This study is based on the hypotheses that fasting and postprandial bile acid levels are a sensitive and specific marker for CF liver disease; and that galactose elimination and manganese levels are another marker of CF liver disease.

本研究基于以下假设：空腹和餐后胆汁 酸水平是CF肝病的敏感和特异性标志物; 半乳糖的消除和锰的水平是另一个标志 CF肝病